Mixed micelles containing lipophilic gadolinium complexes as MRA contrast agents

被引:64
作者
Anelli, PL
Lattuada, L
Lorusso, V
Schneider, M
Tournier, H
Uggeri, F
机构
[1] Bracco SPA, Milano Res Ctr, I-20134 Milan, Italy
[2] Bracco Res SA, CH-1228 Geneva, Switzerland
关键词
blood pool agents; contrast agents; lipophilic gadolinium complexes; mixed micelles; MR angiography; MR imaging;
D O I
10.1016/S1352-8661(01)00107-7
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Mixed micelles; for MRA are multicomponent systems containing a phospholipid, a biocompatible non-ionic surfactant (e.g. Synperonic (R) F-108), and a lipophilic gadolinium. complex. A variety of lipophilic gadolinium complexes were designed taking, into account features such as: (i) nature of ligand (cyclic versus acyclic); (ii) lipophilic moiety; (iii) global charge of the complex; and (iv), nature of bond connecting the complex to the lipophilic moiety. All the lipophilic gadolinium complexes after formulation as mixed micelles show high relaxivities in water and in blood (rat). Mixed micelles containing gadolinium complexes bearing only, one aliphatic. chain cannot be used as, MRA contrast agents because they have a high haemolytic effect. Furthermore, in rats they are quickly, eliminated from the blood stream. These drawbacks are completely circumvented using gadolinium complexes bearing two aliphatic chains. Mixed micelles, containing such complexes show high relaxivities, no haemolytic effect and long blood permanence. This, makes them promising candidates as, MRA contrast agents. However, elimination, which occurs exclusively through the liver, is not complete, even after 7 days. Complexes containing labile (e.g. ester) bonds between the lipophilic moieties and the chelate, subunit are eliminated through both the liver and the kidneys. However, elimination is still not complete after 7 days. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:114 / 120
页数:7
相关论文
共 21 条
  • [1] L-glutamic acid and L-lysine as useful building blocks for the preparation of bifunctional DTPA-like ligands
    Anelli, PL
    Fedeli, F
    Gazzotti, O
    Lattuada, L
    Lux, G
    Rebasti, F
    [J]. BIOCONJUGATE CHEMISTRY, 1999, 10 (01) : 137 - 140
  • [2] ANELLI PL, 2000, Patent No. 0030688
  • [3] BUNDGAARD H, 1991, Drugs of the Future, V16, P443
  • [4] Magnetic resonance angiography with gadomer-17 - An animal study original investigation
    Dong, Q
    Hurst, DR
    Weinmann, HJ
    Chenevert, TL
    Londy, FJ
    Prince, MR
    [J]. INVESTIGATIVE RADIOLOGY, 1998, 33 (09) : 699 - 708
  • [5] NEW COMPOUNDS - FATTY-ACID AND LONG-CHAIN HYDROCARBON DERIVATIVES CONTAINING A STRONG CHELATING AGENT
    ECKELMAN, WC
    KARESH, SM
    REBA, RC
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1975, 64 (04) : 704 - 706
  • [6] SYNTHESIS OF AMPHIPHILIC CHELATING-AGENTS - BIS(HEXADECYLAMIDE) AND BIS(OCTADECYLAMIDE) OF DIETHYLENETRIAMINEPENTAACETIC ACID
    JASANADA, F
    NEPVEU, F
    [J]. TETRAHEDRON LETTERS, 1992, 33 (39) : 5745 - 5748
  • [7] DESIGN, SYNTHESIS, AND ACTIVITY OF MEMBRANE-DISRUPTING BOLAPHILES
    JAYASURIYA, N
    BOSAK, S
    REGEN, SL
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1990, 112 (15) : 5844 - 5850
  • [8] MECHANISMS OF HEMOLYSIS BY SURFACE-ACTIVE AGENTS
    KONDO, T
    [J]. ADVANCES IN COLLOID AND INTERFACE SCIENCE, 1976, 6 (02) : 139 - 172
  • [9] Polymeric gadolinium chelate magnetic resonance imaging contrast agents: Design, synthesis, and properties
    Ladd, DL
    Hollister, R
    Peng, X
    Wei, D
    Wu, G
    Delecki, D
    Snow, RA
    Toner, JL
    Kellar, K
    Eck, J
    Desai, VC
    Raymond, G
    Kinter, LB
    Desser, TS
    Rubin, DL
    [J]. BIOCONJUGATE CHEMISTRY, 1999, 10 (03) : 361 - 370
  • [10] LASIC L, 1995, STEALTH LIPOSOMES